Given that the majority of patients present with heart failure with preserved ejection fraction, the efficacy of SGLT2 inhibitors and the non-steroidal mineralocorticoid receptor antagonist finerenone—which have shown benefits in this phenotype—should be rigorously evaluated. This evidence concerns the gene NR3C2 and heart failure.